NYXOAH SA (NYXH) Stock Price & Overview

NASDAQ:NYXH • BE0974358906

Current stock price

3.12 USD
-0.03 (-0.95%)
Last:

The current stock price of NYXH is 3.12 USD. Today NYXH is down by -0.95%. In the past month the price decreased by -30.51%. In the past year, price decreased by -72.54%.

NYXH Key Statistics

52-Week Range3.05 - 11.87
Current NYXH stock price positioned within its 52-week range.
1-Month Range3.05 - 5.17
Current NYXH stock price positioned within its 1-month range.
Market Cap
136.219M
P/E
N/A
Fwd P/E
N/A
EPS (TTM)
-2.57
Dividend Yield
N/A

NYXH Stock Performance

Today
-0.95%
1 Week
-11.86%
1 Month
-30.51%
3 Months
-35.67%
Longer-term
6 Months -36.84%
1 Year -72.54%
2 Years -76.87%
3 Years -58.23%
5 Years N/A
10 Years N/A

NYXH Stock Chart

NYXOAH SA / NYXH Daily stock chart

NYXH Technical Analysis

ChartMill assigns a technical rating of 0 / 10 to NYXH. When comparing the yearly performance of all stocks, NYXH is a bad performer in the overall market: 96.01% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

NYXH Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to NYXH. Both the profitability and financial health of NYXH have multiple concerns.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

NYXH Earnings

On November 13, 2025 NYXH reported an EPS of -0.63 and a revenue of 1.97M. The company missed EPS expectations (-5.02% surprise) and missed revenue expectations (-1.3% surprise).

Next Earnings DateMar 19, 2026
Last Earnings DateNov 13, 2025
PeriodQ3 / 2025
EPS Reported-€0.63
Revenue Reported1.972M
EPS Surprise -5.02%
Revenue Surprise -1.30%

NYXH Forecast & Estimates

14 analysts have analysed NYXH and the average price target is 11.28 USD. This implies a price increase of 261.59% is expected in the next year compared to the current price of 3.12.

For the next year, analysts expect an EPS growth of -22.05% and a revenue growth 66.9% for NYXH


Analysts
Analysts81.43
Price Target11.28 (261.54%)
EPS Next Y-22.05%
Revenue Next Year66.9%

NYXH Groups

Sector & Classification

Index Membership

NYXH Financial Highlights

Over the last trailing twelve months NYXH reported a non-GAAP Earnings per Share(EPS) of -2.57. The EPS decreased by -30.42% compared to the year before.


Income Statements
Revenue(TTM)5.64M
Net Income(TTM)-83.57M
Industry RankSector Rank
PM (TTM) N/A
ROA -89.29%
ROE -164.01%
Debt/Equity 0.4
Chartmill High Growth Momentum
EPS Q2Q%-27.02%
Sales Q2Q%55.77%
EPS 1Y (TTM)-30.42%
Revenue 1Y (TTM)10.96%

NYXH Ownership

Ownership
Inst Owners21.79%
Shares43.66M
Float27.49M
Ins Owners19.69%
Short Float %0.98%
Short Ratio5.24

NYXH Competitors/Peers

The largest stocks on the US markets in the "Health Care Equipment" sub-industry
Full List
SymbolCompany NameTechnical RatingFundamental RatingFPEMarket Cap
ABT ABBOTT LABORATORIES19.27191.058B
ISRG INTUITIVE SURGICAL INC47.23171.691B
SYK STRYKER CORP23.08133.773B
BSX BOSTON SCIENTIFIC CORP20.36103.561B
EW EDWARDS LIFESCIENCES CORP27.9748.532B
IDXX IDEXX LABORATORIES INC39.646.687B
BDX BECTON DICKINSON AND CO11.8645.635B
RMD RESMED INC19.0233.595B
GEHC GE HEALTHCARE TECHNOLOGY1432.892B
DXCM DEXCOM INC26.4825.532B
ZBH ZIMMER BIOMET HOLDINGS INC10.9118.254B
HOLX HOLOGIC INC15.2916.777B
PODD INSULET CORP35.6515.816B

About NYXH

Company Profile

NYXH logo image Nyxoah SA is a medical technology company, which engages in the development and commercialization of solutions to treat Obstructive Sleep Apnea (OSA). The company is headquartered in Mont-Saint-Guibert, Brabant-Wallon and currently employs 184 full-time employees. The company went IPO on 2020-09-18. The firm focuses on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The system consists of a neurostimulator, which is implanted close to the nerve of the tongue, as well as an activation chip, which is connected to a disposable patch and is positioned every night by the patient under the chin.

Company Info

IPO: 2020-09-18

NYXOAH SA

Rue Edouard Belin 12

Mont-Saint-Guibert BRABANT-WALLON BE

CEO: Olivier Taelman

Employees: 184

NYXH Company Website

NYXH Investor Relations

Phone: 3226121755

NYXOAH SA / NYXH FAQ

What does NYXH do?

Nyxoah SA is a medical technology company, which engages in the development and commercialization of solutions to treat Obstructive Sleep Apnea (OSA). The company is headquartered in Mont-Saint-Guibert, Brabant-Wallon and currently employs 184 full-time employees. The company went IPO on 2020-09-18. The firm focuses on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The system consists of a neurostimulator, which is implanted close to the nerve of the tongue, as well as an activation chip, which is connected to a disposable patch and is positioned every night by the patient under the chin.


Can you provide the latest stock price for NYXOAH SA?

The current stock price of NYXH is 3.12 USD. The price decreased by -0.95% in the last trading session.


What is the dividend status of NYXOAH SA?

NYXH does not pay a dividend.


What is the ChartMill technical and fundamental rating of NYXH stock?

NYXH has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.


Can you provide the number of employees for NYXOAH SA?

NYXOAH SA (NYXH) currently has 184 employees.


What is NYXOAH SA worth?

NYXOAH SA (NYXH) has a market capitalization of 136.22M USD. This makes NYXH a Micro Cap stock.